SCHEMBL22190044

SCHEMBL22190044

CNC(Cc1ccccc1CN)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
MME P08473 4/20 0.39
ACE P12821 3/20 0.39
CPA1 P15085 3/20 0.39
ACE2 Q9BYF1 3/20 0.39
DPP4 P27487 1/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NOS3 P29474 2/20 0.38
NOS1 P29475 2/20 0.38
NOS2 P35228 2/20 0.38
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
GNPAT O15228 1/20 0.37
ALOX15 P16050 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP14 P50281 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22190046 1.00 KMT2A (0.41) KMT2AMMEACECPA1ACE2
SCHEMBL27744244 0.83 KMT2A (0.41) KMT2AMMEACECPA1ACE2
SCHEMBL27744242 0.83 KMT2A (0.41) KMT2AMMEACECPA1ACE2
SCHEMBL8285978 0.82 PPARA (0.50) KMT2AMMEACECPA1ACE2
SCHEMBL10065590 0.81 PPARG (0.48) KMT2AKDM4EALDH1A1GAA
SCHEMBL16203412 0.81 PPARG (0.48) KMT2AKDM4EALDH1A1GAA
SCHEMBL27977570 0.81 PPARG (0.48) KMT2AKDM4EALDH1A1GAA
SCHEMBL29855148 0.81 PPARG (0.48) KMT2AKDM4EALDH1A1GAA
SCHEMBL692547 0.80 CTSS (0.47) KMT2AKDM4EALDH1A1
SCHEMBL20272568 0.80 PPARG (0.49) SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12077611-B2 Cyclic peptides multimers targeting α4β7 integrin ZEALAND PHARMA A/S (DK) 2024-09-03 US disclosed
US-20230406884-A1 CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN ZEALAND PHARMA A/S (DK) 2023-12-21 US disclosed
US-11713338-B2 Cyclic peptides multimers targeting α-4-β-7 integrin ZEALAND PHARMA A/S (DK) 2023-08-01 US disclosed
US-11111273-B2 Cyclic peptides multimers targeting alpha-4-beta-7 integrin ZEALAND PHARMA A/S (DK) 2021-09-07 US disclosed
US-20200216501-A1 CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN ZEALAND PHARMA A/S (DK) 2020-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111273-B2 Cyclic peptides multimers targeting alpha-4-beta-7 integrin ITGB7, ITGB4, ITGA4 KMT2A 4390/4885MME 1213/4885ACE 3447/4885
US-12077611-B2 Cyclic peptides multimers targeting α4β7 integrin ITGB7, ITGB4, ITGA4 KMT2A 4279/4885MME 1825/4885ACE 3178/4885
US-20200216501-A1 CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN ITGB7, ITGB4, ITGA4 KMT2A 4390/4885MME 1213/4885ACE 3447/4885
US-20230406884-A1 CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN ITGB7, ITGB4, ITGA4 KMT2A 4390/4885MME 1213/4885ACE 3447/4885
US-11713338-B2 Cyclic peptides multimers targeting α-4-β-7 integrin ITGB7, ITGB4, ITGA4 KMT2A 4318/4885MME 1406/4885ACE 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.